Organoid-Screening Automation Architect — Translational Research

The mandate

Research groups are scaling patient-derived organoids from artisanal experiments into automated intervention screens. Their systems track plates, images and compounds, but the biological state that determines comparability—source consent, derivation, matrix, passage, morphology, maturation and culture exception—travels in notebooks and local interpretation. Automation can multiply measurements faster than scientists can explain whether two wells represent the same model state.

The deliverable is an Organoid Screening Evidence Architecture for two disease models, covering donor and consent boundary, cell and organoid lineage, culture state, material lot, plate topology, robot action, intervention, imaging acquisition, phenotype extraction, quality flag and scientific disposition. It will preserve expert morphology judgement and prohibit unsupported pooling across biological contexts.

Milestone one at week four produces observed study journeys, variability sources and consequence-ranked evidence gaps. Week ten concludes milestone two with the biological state model and automation contracts. At week eighteen, milestone three supplies reference screens and perturbation exercises. The accepted architecture, migration priorities, supplier schedules and scientist-run qualification pack close milestone four at week twenty-six.

Acceptance requires scientists to reconstruct twelve unseen wells from authorised source through current phenotype and explain whether comparison is valid; a swapped matrix lot and delayed imaging run must propagate visibly; and Quality must reperform sampled lineage. The scientific director signs after internal teams execute a passage-boundary and plate-map corruption scenario without consultant guidance.

The client will provide de-identified model histories, consent constraints, culture and passage records, material lots, robot and imaging logs, analytical pipelines, quality rules, supplier contracts and controlled laboratory access. Client engineers build references; scientists define biological comparability and phenotype meaning. The work excludes wet-lab execution, clinical conclusion, assay validation, production integration and instrument procurement.

Why this is external work

Biologists understand model state and automation teams understand instrument events, but neither owns the evidence boundary between biological variability and technical repeatability. Vendors centre their own device records. External architecture can create a portable study thread and test it adversarially without deciding scientific validity or selling a screening platform.

What you will own

• Map donor boundary, cell source, derivation, passage, culture condition, matrix, organoid, plate, intervention, image, phenotype and disposition.
• Define effective biological state and comparability rules without reducing morphology, maturity and heterogeneity to one platform status.
• Design material and plate identity through aliquot, split, pool, transfer, failed well, repeated measurement and authorised correction.
• Exercise matrix substitution, passage drift, plate-map corruption, delayed imaging, segmentation change and environmental excursion.
• Specify human review where automated phenotype confidence, morphology or quality flags cannot support a scientific comparison.
• Assess laboratory platforms through lineage, open export, timing precision, image provenance, correction, supplier exit and operating burden.
• Transfer evidence-model stewardship and perturbation testing to permanent biology, automation and research-data owners.

Candidate qualifications

• Led organoid, cell-model or high-content screening information architecture across automated translational research programmes.
• Connected donor restrictions, derivation, culture state, passage, materials, interventions, images and analytical phenotypes in reproducible lineage.
• Governed biological variability and technical repeatability without allowing plate completion or model confidence to imply scientific validity.
• Reconstructed studies after matrix change, passage drift, plate-map error, delayed acquisition or altered image segmentation.
• Worked credibly with stem-cell scientists, biostatisticians, automation engineers, Quality and Biosafety under partner scrutiny.
• Delivered vendor-neutral architecture that internal scientists qualified through unseen biological and automation perturbations after closure.

Non-negotiables

• The named architect must lead Chennai laboratory observation and both passage-boundary and plate-corruption acceptance exercises.
• No financial relationship may exist with cell-model, matrix, imaging, automation or research-platform suppliers evaluated.
• Scientists retain biological comparability, phenotype, study and publication decisions; Quality and Biosafety retain formal authority.
• Wet-lab delivery, clinical interpretation, assay validation and production software implementation are expressly excluded.

1. 49 words maximum. Describe an organoid-screening comparison invalidated by biological state rather than instrument performance.
2. 49 words maximum. How did you preserve passage and matrix context through an automated plate workflow?
3. 49 words maximum. Which client evidence is essential before testing a corrupted plate map?